BRTX - BioRestorative Therapies, Inc. Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

BioRestorative - graphic logo of issuer BRTX

BioRestorative Therapies (BRTX) operates a sterile cell cultivation facility in New York, ensuring comprehensive quality control. However, global instability and sanctions are currently complicating biomaterial logistics and international testing. This chart on GURU.Markets shows an EV/EBITDA of 0.00. The company is currently focusing on patenting R&D and advancing its back disease therapy to Phase 2 FDA trials.

BioRestorative Therapies, Inc. - BRTX Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization (period 11/23/2025 - 11/13/2026)

BRTX (biorestorative.com): analytical breakdowns and indicator data

- market price and analyst price targets:
Price Chart BioRestorative Therapies, Inc.|BRTX - Price Target Chart
- market capitalization statistics:
Market Value BRTX|BRTX - Company Buyout Price
- book value of equity indicators:
Book Value per Share BioRestorative Therapies|BRTX - Company Book Value|Market Capitalization to Book Value Ratio biorestorative.com|BRTX - Company Total Asset Base
- company liabilities and liquidity data:
Debt to Equity BioRestorative Therapies|BRTX - Long-Term Liabilities to Capital|Short-Term Debt to Equity BioRestorative Therapies, Inc.|BRTX - Aggregate Debt Obligations|Debts to Book Capitalization BRTX|BRTX - Long-Term Debt|Company Short-Term Debt BioRestorative Therapies|Quick Liquidity Indicator biorestorative.com
- financial results and valuation multiples details:
BRTX - Profit After Payment of Taxes|Expected Profit BioRestorative Therapies|BRTX - Market Cap to Earnings|Future Price to Earnings BioRestorative Therapies, Inc.|BRTX - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple BRTX|BRTX - Operating profit EBITDA|Net earnings per share for the last 12 months BioRestorative Therapies|BRTX - Earnings per share for the last four quarters|Quarterly EPS earnings growth biorestorative.com|BRTX - Expected net earnings per share growth this year|Expected earnings per share growth for next year BioRestorative Therapies
Summary company analysis:BioRestorative BRTX
Original product of BioRestorative Therapies, Inc.

For the BioRestorative Therapies (BRTX) biotech ecosystem and its capital-intensive ThermoStem platform, this indicator determines the business value relative to earnings before interest, taxes, depreciation, and amortization. An analysis of the current EV/EBITDA multiple allows investors to understand how effectively BioRestorative Therapies (BRTX) capitalizes its patents amidst high costs, accounting for total debt and the market value of assets.

Competitor analysis

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Mesoblast Corp MESO|Lineage Corp - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SRZN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Cryo-Cell International CCEL|FBLG: EV/EBITDA Multiple|LGVN (Longeveron Inc) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CELZ (Creative Medical Technology Holdings, Inc.) - EV/EBITDA Multiple